(Currently being updated)

• Perfect, JR. Nuances of new anti-Aspergillus antifungals. Med Mycol. 1:S271-276, 2005.
  
  
• Perfect, JR. Cryptococcus neoformans: A sugar-coated killer with designer genes. FEMS Immunol Med Microbiol. 45:395-404, 2005.
  
  
• Wormley FL Jr., Heinrich G, Miller JL, Perfect JR, and Cox, GM. Identification and characterization of an SKN7 homologue in Cryptococcus neoformans. Infect Immun. 73:5022-5030, 2005.
  
  
• Nielsen K, Cox GM, Litvintseva AP, Mylonakis E, Malliaris SD, Benjamin DK Jr., Giles SS, Mitchell TG, Casadevall A, Perfect JR, and Heitman J. Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection. Infect Immun. 73:4922-4933, 2005.
  
  
• Perfect JR. Posaconazole: A viewpoint by John R. Perfect. Drugs, 65:1568-1569, 2005.
  
  
• Chang CY, Schell WA, Perfect JR, and Hulka GF. Novel use of a swimming pool biocide in the treatment of a rare fungal mastoiditis. Laryngoscope, 115:1065-1069, 2005.
  
  
• Gibbs WJ, Drew RH, and Perfect JR. Liposomal amphotericin B: Clinical experience and perspectives. Expert Rev Anti Infect Ther., 3:167-181, 2005.
  
  
• Wormley FL Jr. and Perfect JR. Immunology of infection caused by Cryptococcus neoformans. Methods Mol Med., 118:193-198, 2005.
  
  
• Drew RH, Arthur RR, and Perfect JR. Is it time to abandon the use of amphotericin B bladder irrigation? Clin Infect Dis., 40:1465-1470, 2005.
  
  
• Venkatesan P, Perfect JR, and Myers SA. Evaluation and management of fungal infections in immunocompromised patients. Dermatol Ther., 18:44-57, 2005.
  
  
• Baddour LM, Perfect JR, Ostrosky-Zeichner L. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis., 6:S409-13, 2005.
  
  
• Perfect JR. Treatment of non-Aspergilus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis., 6:S401-408, 2005.
  
  
• Wormley FL Jr., Cox GM, and Perfect, JR. Evaluation of host immune responses to pulmonary cryptococcosis using a temperature-sensitive C. neoformans calcineurin A mutant strain. Microb Pathog., 38:113-123, 2005.
  
  
• Perfect JR. Antifungal resistance: The clinical front. Oncology (Williston Park). 18:15-22, 2004.
  
  
• Perfect JR. Use of newer antifungal therapies in clinical practice: What do the data tell us? Oncology (Williston Park). 18:15-23, 2004.
  
  
• Cox GM, Durack DT, and Perfect J. Fungal infections and the central nervous system (ed MJ Aminoff). Neurology and General Medicine, 3rd ed., pp 789-807, 2001.
  
  
• Luberto C, Toffaletti DL, Wills EA, Tucker S, Casadevall A, Perfect JR, Hannun YA, Del Poeta M. Roles for inositol-phosphoryl ceramide 1 (IPC1) in pathogenesis of Cryptococcus neoformans. Genes and Dev. 15:201-212, 2001.
  
  
• Wills EA, Roberts IS, Del Poeta M, Cox GM, Rivera J, Casadevall A, Perfect JR. Identification and characterization of the Cryptococcus neoformans phosphomannose isomerase-encoding gene, MAN1, and its impact on pathogenicity. Mol. Microbiol. 40:1-13, 2001.
  
  
• D'Souza C, Alspaugh JA, Yue C, Cox GM, Perfect JR, Heitman J. cAMP dependent protein kinase controls virulence of the fungal pathogen, Cryptococcus neoformans. Mol. Cell. Biol.21:3179-3191, 2001.
  
  
• Stephens CE, Tanious F, Wilson DW, Schell WA, Perfect JR, Fransblau SG, Boykin DW. Diguanidino and "reversed" diamidino 2,5-diarylfurans as antimicrobial agents. J. Med. Chem. 44:1741-1748, 2001.
  
  
• Walsh T, Pappas P, Winston D, Blumer J, Peterson F, Yanovich S, Raffalli J, Stiff P, Greenberg R, Donowitz G, Lee J, Wingard J, Fioritoni G, Finberg R, Laverdiere M, Perfect JR, Schuster M, Arndt C, Reinhardt J, Reboli A, Garber SG, Lynch JR, Ricci P, Anaissie E. Voriconazole compared with liposomal amphotericin B for empiric therapy in patients with neutropenia and persistent fever. N. Engl. J. Med., 34:225-234, 2002.